Strategies to Manage Antibody Drug Conjugates (ADC) - Related Toxicities in Breast Cancer - Episode 7
Overview of Cardiotoxicity Risk with T-DXd and Monitoring Strategies along with Anti-Nausea strategies
Experts on breast cancer discuss the potential adverse events related to trastuzumab deruxtecan (T-DXd).
Video content above is prompted by the following:
- Can you describe the cardiotoxicity risk with T-DXd and the mechanism behind cardiovascular toxicity?
- Please comment on your monitoring strategy for cardiotoxicity with T-DXd.
- What patient symptoms do you monitor for? What are your left ventricular ejection fraction cutoffs to initiate, hold/delay, and discontinue therapy?
Related Content:
